Phase 3 trial of lenvatinib (LEN) vs sorafenib (SOR) in first-line treatment of patients (pts) with unresectable hepatocellular carcinoma (uHCC)

被引：0
|
作者：
Cheng, A. -L. [1 ]
Finn, R. S. [2 ]
Qin, S. [3 ]
Han, K. -H. [4 ]
Ikeda, K. [5 ]
Piscaglia, F. [6 ]
Baron, A. [7 ]
Park, J. -W. [8 ]
Han, G. [9 ]
Jassem, J. [10 ]
Blanc, J. F. [11 ]
Vogel, A. [12 ]
Komov, D. [13 ]
Evans, T. J. [14 ]
Lopez, C. [15 ]
Dutcus, C. [16 ]
Ren, M. [16 ]
Kraljevic, S. [17 ]
Tamai, T. [16 ]
Kudo, M. [18 ]
机构：
[1] Natl Taiwan Univ Hosp, Taipei, Taiwan
[2] UCLA Med Ctr, Geffen Sch Med, Santa Monica, CA USA
[3] Nanjing Bayi Hosp, Nanjing, Jiangsu, Peoples R China
[4] Yonsei Univ, Severance Hosp, Seoul, South Korea
[5] Toranomon Gen Hosp, Tokyo, Japan
[6] Univ Bologna, Bologna, Italy
[7] Calif Pacific Med Ctr, Res Inst, San Francisco, CA USA
[8] Natl Canc Ctr Korea, Goyang Si, South Korea
[9] Fourth Mil Med Univ, Xijing Hosp, Xian, Shaanxi, Peoples R China
[10] Med Univ Gdansk, Gdansk, Poland
[11] Univ Bordeaux, Bordeaux, France
[12] Hannover Med Sch, Hannover, Germany
[13] NN Blokhin Canc Res Ctr, Moscow, Russia
[14] Univ Glasgow, Beatson West Scotland Canc Ctr, Glasgow, Lanark, Scotland
[15] Marques de Valdecilla Univ Hosp, Santander, Spain
[16] Eisai Inc, Woodcliff Lake, NJ USA
[17] Eisai Ltd, Hatfield, PA USA
[18] Kindai Univ, Fac Med, Osaka, Japan
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2017年 / 40卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
'V720
引用
收藏
页码：211 / 211
页数：1
相关论文
共 50 条
  • [1] Phase III Trial of Lenvatinib (LEN) vs Sorafenib (SOR) in First-Line Treatment of Patients (PTS) with Unresectable Hepatocellular Carcinoma (uHCC)
    Cheng, Ann-Lii
    Finn, Richard S.
    Qin, Shukui
    Han, Kwan-Hyub
    Ikeda, Kenji
    Piscaglia, Fabio
    Baron, Ari
    Park, Joong-Won
    Han, Guohong
    Jassem, Jacek
    Blanc, Jean Frederic
    Vogel, Arndt
    Komov, Dmitry
    Evans, T. R. Jeffry
    Lopez, Carlos
    Dutcus, Corina
    MinRen
    Kraljevic, Silvija
    Tamai, Toshiyuki
    Bower, John
    Kudo, Masatoshi
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2017, 13 : 116 - 116
  • [2] Phase III trial of lenvatinib (LEN) vs sorafenib (SOR) in first-line treatment of patients (pts) with unresectable hepatocellular carcinoma (uHCC).
    Cheng, Ann-Lii
    Finn, Richard S.
    Qin, Shukui
    Han, Kwang-Hyub
    Ikeda, Kenji
    Piscaglia, Fabio
    Baron, Ari David
    Park, Joong-Won
    Han, Guohong
    Jassem, Jacek
    Blanc, Jean -Frederic
    Vogel, Arndt
    Komov, Dmitry
    Evans, T. R. Jeffry
    -Lopez, Carlos Lopez
    Dutcus, Corina E.
    Ren, Min
    Kraljevic, Silvija
    Tamai, Toshiyuki
    Kudo, Masatoshi
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [3] Analysis of serum biomarkers (BM) in patients (pts) from a phase 3 study of lenvatinib (LEN) vs sorafenib (SOR) as first-line treatment for unresectable hepatocellular carcinoma (uHCC)
    Finn, R. S.
    Kudo, M.
    Cheng, A-L.
    Wyrwicz, L.
    Ngan, R.
    Blanc, J-F.
    Baron, A. D.
    Vogel, A.
    Ikeda, M.
    Piscaglia, F.
    Han, K-H.
    Qin, S.
    Minoshima, Y.
    Funahashi, Y.
    Ren, M.
    Dairiki, R.
    Sachdev, P.
    Tamai, T.
    Dutcus, C.
    Evans, T. R. J.
    ANNALS OF ONCOLOGY, 2017, 28
  • [4] Independent imaging review (IIR) results in a phase 3 trial of lenvatinib (LEN) versus sorafenib (SOR) in first-line treatment of patients (pts) with unresectable hepatocellular carcinoma (uHCC).
    Lencioni, Riccardo
    Kudo, Masatoshi
    Finn, Richard S.
    Qin, Shukui
    Han, Kwang-Hyub
    Ikeda, Kenji
    Cheng, Ann-Lii
    Piscaglia, Fabio
    Han, Guohong
    Ikeda, Masafumi
    Simon, Krzysztof
    Komov, Dmitry
    OuYang, Xuenong
    Evans, T. R. Jeffry
    Sung, Max W.
    Binder, Terri A.
    Damon, Andrew
    Kraljevic, Silvija
    Ren, Min
    Ryoo, Baek-Yeol
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [5] Efficacy of lenvatinib (LEN) vs sorafenib (SOR) in the first-line (1L) treatment of patients (pts) with unresectable hepatocellular carcinoma (uHCC): A post hoc analysis of patients with nonviral etiology from REFLECT
    Baron, Ari David
    Lopez, Carlos Lopez
    Chang, Stephen Lam
    Piscaglia, Fabio
    Ramji, Zahra
    Ren, Min
    Estenson, Kasey
    Vogel, Arndt
    Gholam, Pierre
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [6] Final analysis of serum biomarkers in patients (pts) from the phase III study of lenvatinib (LEN) vs sorafenib (SOR) in unresectable hepatocellular carcinoma (uHCC) [REFLECT]
    Finn, R. S.
    Kudo, M.
    Cheng, A-L.
    Wyrwicz, L.
    Ngan, R.
    Blanc, J. F.
    Baron, A. D.
    Vogel, A.
    Ikeda, M.
    Piscaglia, F.
    Han, K-H.
    Qin, S.
    Minoshima, Y.
    Kanekiyo, M.
    Ren, M.
    Dairiki, R.
    Tamai, T.
    Dutcus, C. E.
    Funahashi, Y.
    Evans, T. R. J.
    ANNALS OF ONCOLOGY, 2018, 29
  • [7] ctDNA analysis of patients (pts) with unresectable hepatocellular carcinoma (uHCC) treated with lenvatinib (LEN) or sorafenib (SOR) as 1L therapy
    Evans, T. R. Jeffry
    Kudo, Masatoshi
    Cheng, Ann-Lii
    Wyrwicz, Lucjan S.
    Ngan, Roger Kc
    Blanc, Jean-Frederic
    Baron, Ari David
    Vogel, Arndt
    Ikeda, Masafumi
    Piscaglia, Fabio
    Qin, Shukui
    Hoshi, Taisuke
    Tamaki, Ryuji
    Funahashi, Yasuhiro
    Okpara, Chinyere E.
    Sagane, Koji
    Xing, Dongyuan
    Minoshima, Yukinori
    Finn, Richard S.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [8] Nivolumab (NIVO) plus ipilimumab (IPI) vs lenvatinib (LEN) or sorafenib (SOR) as first-line treatment for unresectable hepatocellular carcinoma (uHCC): First results from CheckMate 9DW.
    Galle, Peter Robert
    Decaens, Thomas
    Kudo, Masatoshi
    Qin, Shukui
    Fonseca, Leonardo
    Sangro, Bruno
    Karachiwala, Hatim
    Park, Joong-Won
    Gane, Edward
    Pinter, Matthias
    Tai, David
    Santoro, Armando
    Pizarro, Gonzalo
    Chiu, Chang-Fang
    Schenker, Michael
    He, Aiwu Ruth
    Wang, Qi
    Stromko, Caitlyn
    Hreiki, Joseph
    Yau, Thomas
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (17_SUPPL) : LBA4008 - LBA4008
  • [9] A phase 1b trial of lenvatinib (LEN) plus pembrolizumab (PEM) in patients (pts) with unresectable hepatocellular carcinoma (uHCC).
    Ikeda, Masafumi
    Sung, Max W.
    Kudo, Masatoshi
    Kobayashi, Masahiro
    Baron, Ari David
    Finn, Richard S.
    Kaneko, Shuichi
    Zhu, Andrew X.
    Kubota, Tomoki
    Kraljevic, Silvija
    Ishikawa, Kohei
    Siegel, Abby B.
    Kumada, Hiromitsu
    Okusaka, Takuji
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [10] The first-line treatment for unresectable hepatocellular carcinoma patients: lenvatinib versus sorafenib, or beyond?
    Xie, Feihu
    Feng, Shi
    Sun, Lejia
    Mao, Yilei
    HEPATOBILIARY SURGERY AND NUTRITION, 2018, 7 (03) : 221 - 224
12345